Several other equities research analysts have also commented on CRSP. Zacks Investment Research upgraded Crispr Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th. Piper Jaffray Companies restated a buy rating and issued a $22.75 price objective (down previously from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. SunTrust Banks restated a buy rating and issued a $65.00 price objective on shares of Crispr Therapeutics in a research report on Friday, March 9th. Barclays upped their price objective on Crispr Therapeutics from $29.00 to $59.00 and gave the stock an overweight rating in a research report on Wednesday, March 7th. Finally, ValuEngine upgraded Crispr Therapeutics from a sell rating to a hold rating in a research report on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $53.53.
Shares of Crispr Therapeutics stock opened at $51.52 on Friday. Crispr Therapeutics has a 52-week low of $13.50 and a 52-week high of $61.24. The company has a market capitalization of $2,431.95, a P/E ratio of -29.95 and a beta of 3.63.
In other news, insider Tyler Dylan-Hyde sold 31,000 shares of the stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $22.72, for a total transaction of $704,320.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Thomas Woiwode sold 3,059 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $20.29, for a total value of $62,067.11. Following the transaction, the director now owns 4,959 shares in the company, valued at approximately $100,618.11. The disclosure for this sale can be found here. Insiders have sold a total of 283,850 shares of company stock worth $7,261,865 in the last quarter. Insiders own 39.98% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Farallon Capital Management LLC purchased a new position in shares of Crispr Therapeutics during the 4th quarter valued at approximately $20,160,000. Franklin Resources Inc. lifted its position in shares of Crispr Therapeutics by 8.9% during the 4th quarter. Franklin Resources Inc. now owns 794,533 shares of the company’s stock valued at $18,656,000 after buying an additional 65,200 shares in the last quarter. Global Thematic Partners LLC lifted its position in shares of Crispr Therapeutics by 11.2% during the 4th quarter. Global Thematic Partners LLC now owns 633,452 shares of the company’s stock valued at $14,873,000 after buying an additional 63,611 shares in the last quarter. BlackRock Inc. lifted its position in shares of Crispr Therapeutics by 16,623.9% during the 4th quarter. BlackRock Inc. now owns 552,558 shares of the company’s stock valued at $12,974,000 after buying an additional 549,254 shares in the last quarter. Finally, Opaleye Management Inc. purchased a new position in shares of Crispr Therapeutics during the 4th quarter valued at approximately $6,597,000. Hedge funds and other institutional investors own 26.61% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Crispr Therapeutics (CRSP) Upgraded to C at TheStreet” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/20/crispr-therapeutics-crsp-upgraded-to-c-at-thestreet.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.